<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04407689</url>
  </required_header>
  <id_info>
    <org_study_id>CLI107 COVID FR (ILIAD-7-FR)</org_study_id>
    <nct_id>NCT04407689</nct_id>
  </id_info>
  <brief_title>InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort</brief_title>
  <acronym>ILIAD-7-FR</acronym>
  <official_title>A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amarex Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Revimmune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for&#xD;
      two weeks on immune reconstitution of lymphopenic COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately forty-eight (48) participants will be randomized 1:1 to receive (a)&#xD;
      Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation,&#xD;
      by 10 μg/kg twice a week for 2 weeks or (b) Intramuscular (IM) placebo (normal saline) at the&#xD;
      same frequency. An interim safety review took place after the first 12 patients. Since the&#xD;
      CYT107 was well tolerated, the test dose (3 μg/kg) ceased and the initial dose became the&#xD;
      same as the rest of the doses (10 μg/kg). So, the remaining patients will be randomized to&#xD;
      receive 5 administrations of (a) CYT107 at 10 μg/kg every 3 to 4 days for 2 weeks or (b)&#xD;
      Intramuscular (IM) placebo (normal saline) at the same frequency. The aim of the study is to&#xD;
      test the ability of CYT107 to produce an immune reconstitution of these patients and observe&#xD;
      possible association with a clinical improvement&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor accrual&#xD;
  </why_stopped>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Actual">March 30, 2022</completion_date>
  <primary_completion_date type="Actual">March 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled of treatment vs placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first</measure>
    <time_frame>1 month</time_frame>
    <description>A statistically significant increase of the absolute lymphocyte count (ALC) from randomization to day 30 or Hospital Discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To obtain &quot;clinical improvement&quot; as defined by an improvement in a 11-points WHO score for Clinical Assessment, through day 30 or HD.</measure>
    <time_frame>1 month</time_frame>
    <description>to determine if CYT107 will improve the clinical status of hospitalized COVID-19 patients as measured by 11 steps WHO clinical improvement score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a significant decline of SARS-CoV-2 viral load through day 30 or HD</measure>
    <time_frame>1 month or HD (whichever occurs first)</time_frame>
    <description>The decrease of SARS-CoV-2 viral load from measurements at baseline and days of treatment dose 4 and dose 5, Day 21 and Day 30 or HD (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of secondary infections through day 45 compared tp placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Incidence of secondary infections based on pre-specified criteria as adjudicated by the Secondary Infections Committee (SIC) through Day 45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospitalization compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Number of days of hospitalization during index hospitalization (defined as time from initial Study drug treatment through HD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay in ICU compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Number of days in ICU during index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of readmissions to ICU compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Readmissions to ICU through Day 45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>organ support free days compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Organ support free days (OSFDs) during index hospitalization (This includes ventilator assistance free days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of re-hospitalization through day 45 compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>Number of readmissions to the hospital through Day 45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality through day 45 compared to placebo arm</measure>
    <time_frame>45 days</time_frame>
    <description>All-cause mortality through Day 45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ and CD8+ T cell counts compared to placebo arm</measure>
    <time_frame>30 days</time_frame>
    <description>Absolute numbers of CD4+ and CD8+ T-cell counts at timepoints indicated on the Schedule of Activities (SoA) through Day 30 or HD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of other known biomarkers of inflammation: Ferritin compared to placebo arm</measure>
    <time_frame>30 days</time_frame>
    <description>Track and evaluate other known biomarkers of inflammation, Ferritin, from baseline to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of other known biomarkers of inflammation: CRP compared to placebo arm</measure>
    <time_frame>30 days</time_frame>
    <description>Track and evaluate other known biomarkers of inflammation, CRP from baseline to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of other known biomarkers of inflammation: D-dimer compared to placebo arm</measure>
    <time_frame>30 days</time_frame>
    <description>Track and evaluate other known biomarkers of inflammation, D-dimer from baseline to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological status through NEWS2 evaluation compared to Placebo arm</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate improvement of the NEWS2 score value. Score form 0 to 4: NO Risk Score of 7 or more: High risk</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety assessment through incidence and scoring of grade 3-4 adverse events</measure>
    <time_frame>45 days</time_frame>
    <description>Incidence and scoring of all grade 3-4 adverse events through Day 45 (using CTCAE Version 5.0 to assess severity)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>COVID-19</condition>
  <condition>Lymphocytopenia</condition>
  <arm_group>
    <arm_group_label>CYT107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-muscular administration of CYT107 twice a week for a total of 5 administrations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-7</intervention_name>
    <description>Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or</description>
    <arm_group_label>CYT107</arm_group_label>
    <other_name>CYT107</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular (IM) placebo (normal saline) at the same frequency</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A written, signed informed consent, or emergency oral consent, by the patient or the&#xD;
             patient's legally authorized representative, and the anticipated ability for&#xD;
             participant to be re-consented in the future for ongoing Study participation&#xD;
&#xD;
          -  Men and women aged ≥ 25 - 80 (included) years of age&#xD;
&#xD;
          -  Hospitalized patients with one absolute lymphocyte count (ALC) ≤ 1000 cells/mm3,&#xD;
             collected at baseline or no more than 72h before baseline&#xD;
&#xD;
          -  Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at&#xD;
             &gt;4L per minute nasal cannula or greater to keep saturations &gt;90%, non-invasive&#xD;
             positive pressure ventilation (e.g., BIPAP) for respiratory failure&#xD;
&#xD;
          -  Confirmed infection with COVID-19 by any acceptable test available/ utilized at each&#xD;
             site&#xD;
&#xD;
          -  Patient with medical insurance or government support&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding;&#xD;
&#xD;
          -  Refusal or inability to practice contraception regardless of the gender of the&#xD;
             patient;&#xD;
&#xD;
          -  ALT and/or AST &gt; 5 x ULN&#xD;
&#xD;
          -  Known, active auto-immune disease;&#xD;
&#xD;
          -  Ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy&#xD;
             within last 3 months and/or ongoing;&#xD;
&#xD;
          -  Patients with past history of Solid Organ transplant.&#xD;
&#xD;
          -  Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral&#xD;
             load.&#xD;
&#xD;
          -  Patients whose respiratory condition is showing significant deterioration as indicated&#xD;
             by:&#xD;
&#xD;
               -  8a requirement for an increase in inspired oxygen concentrations of 20% or more&#xD;
                  over the past 24 hours to maintain SpO2 at greater than or equal to 88%&#xD;
&#xD;
               -  8b or need for invasive mechanical ventilation&#xD;
&#xD;
          -  Patients showing an increase of the NEWS2 score by more than 6 points during the&#xD;
             screening / baseline period (48 to 72 hrs prior to first administration)&#xD;
&#xD;
          -  Patients with chronic kidney dialysis&#xD;
&#xD;
          -  Patients with a SOFA score ≥ 9 at baseline&#xD;
&#xD;
          -  Patients with a BMI &gt; 40&#xD;
&#xD;
          -  Patients receiving any agent with immune suppressive effects,such as anti-IL6&#xD;
             treatments like Tocilizumab or Sarilumab which should preferably be minimized&#xD;
&#xD;
          -  Presence of any of the following abnormal laboratory values at screening: absolute&#xD;
             neutrophil count (ANC) &lt; 1.5x109/L, Platelets &lt; 50,000 per mm3&#xD;
&#xD;
          -  Patients with uncontrolled pre-existing severe major organ dysfunction (cardiac, liver&#xD;
             or renal failure)&#xD;
&#xD;
          -  Vaccination with live attenuated vaccines in the month preceding the inclusion&#xD;
&#xD;
          -  Use of chronic oral corticosteroids ≥ 10mg prednisone equivalent a day for a&#xD;
             non-COVID-19 related condition&#xD;
&#xD;
          -  Patients with baseline Rockwood Clinical Frailty Scale ≥ 6.&#xD;
&#xD;
          -  Patients with known hypersensitivity to natural or recombinant Interleukin-7 or to any&#xD;
             of the excipients&#xD;
&#xD;
          -  Patients under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno François, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr Orleans La Source</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>hopital COCHIN</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmele T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J, Durum SK, Sherwood ER, Hotchkiss RS. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018 Mar 8;3(5):e98960. doi: 10.1172/jci.insight.98960.</citation>
    <PMID>29515037</PMID>
  </reference>
  <reference>
    <citation>Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, Monneret G. IL-7 restores lymphocyte functions in septic patients. J Immunol. 2012 Nov 15;189(10):5073-81. doi: 10.4049/jimmunol.1202062. Epub 2012 Oct 10.</citation>
    <PMID>23053510</PMID>
  </reference>
  <results_reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.</citation>
    <PMID>32031570</PMID>
  </results_reference>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>March 30, 2022</last_update_submitted>
  <last_update_submitted_qc>March 30, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Lymphopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04407689
org study id: CLI107 COVID FR (ILIAD-7-FR)
nct id: NCT04407689
lead sponsor: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for
      two weeks on immune reconstitution of lymphopenic COVID-19 patients.
Approximately forty-eight (48) participants will be randomized 1:1 to receive (a)
      Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation,
      by 10 μg/kg twice a week for 2 weeks or (b) Intramuscular (IM) placebo (normal saline) at the
      same frequency. An interim safety review took place after the first 12 patients. Since the
      CYT107 was well tolerated, the test dose (3 μg/kg) ceased and the initial dose became the
      same as the rest of the doses (10 μg/kg). So, the remaining patients will be randomized to
      receive 5 administrations of (a) CYT107 at 10 μg/kg every 3 to 4 days for 2 weeks or (b)
      Intramuscular (IM) placebo (normal saline) at the same frequency. The aim of the study is to
      test the ability of CYT107 to produce an immune reconstitution of these patients and observe
      possible association with a clinical improvement
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: randomized controlled of treatment vs placebo
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
masking description: Double blind
measure: Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first
time frame: 1 month
description: A statistically significant increase of the absolute lymphocyte count (ALC) from randomization to day 30 or Hospital Discharge
measure: To obtain "clinical improvement" as defined by an improvement in a 11-points WHO score for Clinical Assessment, through day 30 or HD.
time frame: 1 month
description: to determine if CYT107 will improve the clinical status of hospitalized COVID-19 patients as measured by 11 steps WHO clinical improvement score
measure: a significant decline of SARS-CoV-2 viral load through day 30 or HD
time frame: 1 month or HD (whichever occurs first)
description: The decrease of SARS-CoV-2 viral load from measurements at baseline and days of treatment dose 4 and dose 5, Day 21 and Day 30 or HD (whichever occurs first)
measure: frequency of secondary infections through day 45 compared tp placebo arm
time frame: 45 days
description: Incidence of secondary infections based on pre-specified criteria as adjudicated by the Secondary Infections Committee (SIC) through Day 45
measure: length of hospitalization compared to placebo arm
time frame: 45 days
description: Number of days of hospitalization during index hospitalization (defined as time from initial Study drug treatment through HD)
measure: length of stay in ICU compared to placebo arm
time frame: 45 days
description: Number of days in ICU during index hospitalization
measure: number of readmissions to ICU compared to placebo arm
time frame: 45 days
description: Readmissions to ICU through Day 45
measure: organ support free days compared to placebo arm
time frame: 45 days
description: Organ support free days (OSFDs) during index hospitalization (This includes ventilator assistance free days)
measure: Frequency of re-hospitalization through day 45 compared to placebo arm
time frame: 45 days
description: Number of readmissions to the hospital through Day 45
measure: All-cause mortality through day 45 compared to placebo arm
time frame: 45 days
description: All-cause mortality through Day 45
measure: CD4+ and CD8+ T cell counts compared to placebo arm
time frame: 30 days
description: Absolute numbers of CD4+ and CD8+ T-cell counts at timepoints indicated on the Schedule of Activities (SoA) through Day 30 or HD
measure: level of other known biomarkers of inflammation: Ferritin compared to placebo arm
time frame: 30 days
description: Track and evaluate other known biomarkers of inflammation, Ferritin, from baseline to day 30
measure: Level of other known biomarkers of inflammation: CRP compared to placebo arm
time frame: 30 days
description: Track and evaluate other known biomarkers of inflammation, CRP from baseline to day 30
measure: Level of other known biomarkers of inflammation: D-dimer compared to placebo arm
time frame: 30 days
description: Track and evaluate other known biomarkers of inflammation, D-dimer from baseline to day 30
measure: Physiological status through NEWS2 evaluation compared to Placebo arm
time frame: 30 days
description: Evaluate improvement of the NEWS2 score value. Score form 0 to 4: NO Risk Score of 7 or more: High risk
measure: Safety assessment through incidence and scoring of grade 3-4 adverse events
time frame: 45 days
description: Incidence and scoring of all grade 3-4 adverse events through Day 45 (using CTCAE Version 5.0 to assess severity)
arm group label: CYT107
arm group type: Experimental
description: Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
arm group label: Saline
arm group type: Placebo Comparator
description: Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
intervention type: Drug
intervention name: Interleukin-7
description: Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
arm group label: CYT107
other name: CYT107
intervention type: Drug
intervention name: Placebo
description: Intramuscular (IM) placebo (normal saline) at the same frequency
arm group label: Saline
other name: Saline
criteria: 
gender: All
minimum age: 25 Years
maximum age: 80 Years
healthy volunteers: No
last name: Bruno François, MD
role: Study Chair
affiliation: University Hospital, Limoges
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: France
citation: Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmele T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J, Durum SK, Sherwood ER, Hotchkiss RS. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018 Mar 8;3(5):e98960. doi: 10.1172/jci.insight.98960.
PMID: 29515037
citation: Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, Monneret G. IL-7 restores lymphocyte functions in septic patients. J Immunol. 2012 Nov 15;189(10):5073-81. doi: 10.4049/jimmunol.1202062. Epub 2012 Oct 10.
PMID: 23053510
citation: Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.
PMID: 32171076
citation: Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.
PMID: 32031570
responsible party type: Sponsor
mesh term: COVID-19
mesh term: Lymphopenia
sharing ipd: No
ipd description: publication